Altered GABAergic Signaling in Brain Disease at Various Stages of Life

Yoo Sung Kim and Bo-Eun Yoon*
Department of Molecular Biology, Dankook University, Cheonan 31116, Korea

In the healthy brain, gamma-aminobutyric acid (GABA) is regulated by neurons and glia. This begs the question: what happens in the malfunctioning brain? There are many reasons why diseases occur, including genetic mutations, systemic problems, and environmental influences. There are also many ways in which GABA can become dysregulated, such as through alterations in its synthesis or release, and changes in systems that respond to it. Notably, dysregulation of GABA can have a large impact on the brain. To date, few reviews have examined brain diseases in which dysregulation of GABA is implicated as an underlying factor. Accordingly, the time is ripe for investigating alterations in GABAergic signaling that may play a role in changes in neuronal activity observed in the major brain disorders that occur during various stages of life. This review is meant to provide a better understanding of the role of GABA in brain health and contributor to social problems from a scientific perspective.

Key words: GABA, brain disorder, lifespan, excitatory/inhibitory balance, neurodegenerative disease, neurodevelopmental disease

Received March 19, 2017, Revised May 6, 2017, Accepted May 15, 2017

*To whom correspondence should be addressed. TEL: 82-41-550-3694, FAX: 82-41-559-7941 e-mail: boeunyoon@dankook.ac.kr

Copyright © Experimental Neurobiology 2017. www.enjournal.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
the review is to establish the role of GABA in basic brain function and identify GABA-related mechanisms of neural diseases that can have an impact from the cradle to the grave (Fig. 1).

**GABAergic Signaling in Pathological States**

GABAergic inhibition takes two forms: phasic and tonic. Tonic inhibition involves a persistent inhibitory current mediated by high-affinity perisynaptic or extrasynaptic GABA receptors that is initiated in response to ambient or extracellular GABA levels (Fig. 2) [15]. Phasic activation of GABA receptors is important for controlling the rhythm of neuronal activities, whereas tonic activation of these receptors occurs mainly in glia, without the influence of neuronal activity [15]. The tonic current enables inhibition to be shunted so as to control the gain in neuronal excitability [16]. In addition, the effects of tonic GABAergic inhibition can be more subtle because they are mediated by GABA binding to high-affinity GABA receptors [17].

**GABAA receptor**

The GABAA receptor is a ligand-gated ion channel that, when activated, mediates influx of chloride ions and induces hyperpolarization in postsynaptic neurons. GABA acts as an inhibitory neurotransmitter at this receptor [18, 19]. The GABAA receptor is composed of five subunits, which can be combined in a total of 19 ways. The various receptor combinations produce specific traits and are localized to different brain regions [20]. When mutations occur in GABAA receptor subunits, these receptors are unable to respond effectively to GABA released from presynaptic neurons and glia [18]. In addition, in some pathological conditions, the number of GABAA receptors is decreased [20], which has an effect similar to that observed with some mutations. GABAA receptors can be divided into two groups. Group one consists of GABAA receptors that respond to diazepam, a drug that binds to GABAA receptors and induces a calming behavioral effect. Group two receptors, referred to as GABAg receptors, are insensitive to diazepam. The fact that GABAA receptors can be subdivided into receptors that respond to diazepam or not means that the drugs used to treat diseases linked to GABAA receptors must be carefully selected [21].

**GABAg receptor**

The GABAg receptor is a metabotropic G-protein-coupled receptor [22] that serves a secondary messenger function in GABAergic signaling. Because activation of GABAg receptors requires postsynaptic G-protein activation, postsynaptic GABAA receptors increase the activity of extrasynaptic GABAg receptors. Presynaptic GABAg receptors activate the ambient form of GABA in the synapse, thereby increasing the total amount of GABA available, which in turn activates the GABAA receptor [23]. GABAg receptors can be divided into two groups. Receptors in the first are referred to as GABAg1, whereas those in the second are referred to as GABAg2. GABAg1 activates neurons, and GABAg2 is involved in signaling and membrane targeting [24]. The GABAg1 receptor can be further subdivided into GABAg1α and GABAg1β subtypes. GABAg1α contains a specific domain called "sushi," which causes localization of GABAg1α to the presynaptic terminals of excitatory synapses; it can also regulate glutamate release. In contrast, GABAg1β receptors are found at postsynaptic terminals [24]. Evidence from GABAg1α-knockout (KO) mice showing that neuronal differentiation and the number of neuronal progenitor cells are in-

---

Fig. 1. Three main axes of brain disease categories during a lifespan. During the course of aging, the flexibility of living organisms and their ability to regenerate neuronal cells decreases. In the early stages of life, curable developmental diseases are the rule owing to the high plasticity and capacity for regeneration that prevail during this period. As people age and become adults, various mood-associated disorders dominate as the flexibility of the brain decreases owing to the stresses and pressure of life. Finally, in the later stages, the brain is rigid, reflecting the aging of our body. People at this stage often suffer from degenerative disorders, such as dementia and movement disorders.
increased in these animals suggests that the GABA$_	ext{A}$ receptor affects neurogenesis in adults [25]. The association of the GABA$_	ext{A}$ receptor with neurogenesis is related to stress and emotional changes; these changes, in turn, affect hippocampal volume, which is closely associated with psychological problems [26].

**GABA transporter**

The GABA transporter (GAT) is expressed mainly on glial cells. There are four GABA transporters: GAT-1, GAT-2 and GAT-3, and betaine GABA transporter (BGT)-1. For the most part, we will focus on GAT-1 here as it accounts for the majority of GABA uptake in astrocytes [27, 28], which are responsible for taking up extrasynaptic GABA (eGABA). GAT appears to be closely related to tonic GABA inhibition [29]. When GAT activation is reduced and the uptake of the eGABA is decreased, eGABA concentrations are maintained at high levels [30]. For this reason, GAT is an important player in the mechanism of action of GABA.

**EARLY STAGES OF LIFE**

In the early stages of life, many parts of the brain and body are still adjusting to the environments that the newborn infants are encountering [31]. This implies that many disorders that occur at this stage of life might be cured naturally as the children grow up. Here, we describe the following early-stage brain disorders: ADHD, ASD, and epilepsy [32].

**ADHD**

ADHD is characterized by inattention, hyperactivity, and impulsivity [33]. Almost 10% of all children 4–17 years of age are diagnosed with ADHD [34]. ADHD may be caused by intense stress early in life that induces changes in the nervous system [35]. Since patients with ADHD lose control over their behavior, it is thought that ADHD is related to alterations in the brain inhibitory system, in particular, the inhibitory neurotransmitter GABA [34]. A previous study suggested that ADHD is related to the dopaminergic system and specifically to dopamine receptor 1 (DAP1) [36].
Although it has not yet been possible to definitively link this to GABA, numerous studies to date have focused on the GABA receptors. GABA_A and GABA_B. An examination of GABA_A receptor variants has shown that polymorphisms in the X-linked GABRA3 gene and the GABRB3 gene account for about 1.4% of the variance in ADHD [37]. It has also been shown that expression of various GABA_A receptor subunits is decreased in ADHD [37]. Interestingly, ADHD is usually co-morbid with other diseases, such as ASD. A genetic study of ADHD and ASD family groups revealed that the GABRQ gene, which encodes a GABAA receptor subunit, as well as GABRA3, are associated with both ADHD and ASD [38]. The literature also suggests that glutamate levels are related to the intensity of ADHD traits, such as inattention and hyperactivity. However, recent genome-wide association studies (GWAS) and proteomic studies failed to identify polygenetic differences that affect glutamate or GABA between healthy controls and patients [39]. Additional genes that have yet to be identified may also be associated with ADHD [39]. A study performed on spontaneously-hypertensive rats (SHRs), a widely used animal model of ADHD, showed that the GABA_A receptor is sensitive to stressors, especially in the hippocampus [35]. GABA receptor variants may result in alterations in GABAergic signaling and steadily changed levels of GABA affect glutamate transmission and associated norepinephrine (NE) transmission [37]. In the latter case, stress may decrease hippocampal GABA_A receptor numbers, which in turn would result in changes in NE levels. This decrease in tonic GABA and increase in NE found in SHRs may explain the abnormalities observed in ADHD [35, 40].

Autism spectrum disorder

ASD is the second most common brain disease in children and, as mentioned above, it is related to ADHD [38]. Individuals with autism can display a range of symptoms; therefore, autism-related diseases are referred to as comprising a spectrum, a concept that incorporates Asperger’s syndrome, pervasive developmental disorder, autistic disorder, and childhood disintegrative disorder [41]. Patients with diagnoses encapsulated by the umbrella term of ASD have specific traits, such as social deficits, impaired communication, and repetitive behaviors [42]. A comparison of ASD patients with healthy controls showed that the social deficits observed in ASD may be caused by hyperconnectivity in certain regions of the brain [43]. However, ASDs are mainly thought to be caused by an E/I imbalance, which may be induced by alterations in GABAergic signaling and GABA levels [44]. Significantly lower glutamate/GABA ratios have been found in patients with ASD [44]. Changes in GABA and glutamate may cause chronic developmental problems, reflecting the fact that these neurotransmitters are important for brain development and the maintenance of E/I balance during the early stages of life [43, 44]. As described above, there are a variety of different GABA_A receptor subtypes and subunits that can come together to form different types of GABA_A receptors, each of which may have slightly different functions. However, GABA_A receptors in the brains of patients with ASD lack diversity [45]. Such alterations in GABA_A receptors may cause ASD and epileptic symptoms. Moreover, the density of GABA_A and GABA_B receptors in the cortex is decreased in patients with ASD [45]. Studies of transgenic models of ASD have identified mutations in the GABA_A receptor, but not the GABA_B receptor [44]. However, although the GABA_A receptor has relatively little direct effect in ASD, it may impact the GABA_A receptor. Thus, targeting the GABA_A receptor may be an indirect way of treating ASD. In cases where output signals from GABAergic neurons are increased in normal mice, the GABA_A receptor responds and produces impairments in long-term potentiation (LTP), highlighting the importance of the GABA_A receptor [42]. Alterations in the secretion of GABA from GABAergic neurons differ from region to region in ASD. For example, in the subcircuitum, tonic GABA currents are decreased, whereas phasic currents are unaltered [42]. On the other hand, tonic and phasic GABA currents are both reduced in the amygdala [42, 45].

Epilepsy

The overall prevalence of epilepsy is approximately 10 per 1000 individuals, but differs among countries and regions, and occurs more frequently in men than in women [46]. Epilepsy occurs in all age groups, although it most commonly occurs during infancy and childhood. Childhood epilepsy occurs at about twice the rate of adult epilepsy [47]. Since epilepsy is caused by the abnormal firing of neuronal systems, it can be detected by electroencephalography (EEG).

Several types of epilepsy exist, with the two main types being generalized seizures and focal seizures. Generalized seizures occur in both hemispheres, whereas focal seizures occur in specific areas of the brain. These two types of epilepsy can be further divided according to the duration and location of the seizures [48]. Epilepsy, like ASD, can also be considered a spectrum disorder, reflecting the number of different types of seizures and the variations in their etiology and comorbidities [49, 50]. Differences in comorbidities associated with various types of epilepsy, age, sex, and seizure type influence the selection of drugs used to treat the condition [51]. Epilepsy that occurs at a young age usually exhibits ionic changes in the GABA_A receptor and alterations in the E/I balance of the brain [52]. It has been shown that the loss of postsynaptic GABA_A receptors and cation-chloride cotransporters (KCC2) is associated with tyrosine kinase B (TrkB), a receptor tyrosine kinase [52]. En-
hanced activation of TrkB in mature neurons decreases surface expression of the GABA$_A$ receptor [52]. In addition, seizure-induced downregulation of KCC2 activity is dependent on posttranscriptional mechanisms, including cleavage by the protease calpain [53]. A number of studies have suggested that activation of calpain plays a role in epileptogenesis, as evidenced by its important effects on GABAergic signaling [52, 53]. Adult epilepsy is usually just a partial form of epilepsy, and its primary causes include trauma, injury, and tumors [21].

Drugs that target GABA$_A$ receptors with high affinity [54] are used in the treatment of epilepsy. The structure and function of synaptic and extrasynaptic GABA$_A$ receptors provides numerous opportunities to create improved therapies for sleep, anxiety, stress, epilepsy, and other kinds of neuropsychiatric conditions.

GAT-1 also contributes to this disease. As noted above, GAT-1 is one of the major GABA transporters and is responsible for the uptake of synaptic GABA. Accordingly, GAT 1 at synapses represents an excellent target candidate for drugs designed to treat epilepsy [21].

**MATURE STAGE OF LIFE**

Unlike the brains of infants and children, the brains of adults exhibit little neurogenesis or gliogenesis. As the number of newborn cells decreases and events that result in the loss of neurons and astrocytes increase, the volume of the brain decreases. This may be the cause of mood disorders later in life [54]. At this stage of life, GABA is inactivated by uptake into presynaptic terminals or glial cells, which is mediated by GATs [55, 56].

**Depression**

Depression is one of the most concerning psychiatric diseases in society today, owing to the high rates of suicide associated with it. The risk for depression increases with age, with the highest rates occurring in women in the 40–59 year age bracket. Depression, which can affect work life, home life and the survival of patients [57], may be caused by environmental factors, like childhood trauma or genetic problems [58, 59]. Depression is not only a problem for individuals and their families, it also places an economic and obligatory burden on society [60].

Magnetic resonance imaging (MRI) studies have shown a reduction in hippocampal volume in depression [58]. Decreases in hippocampal volume are thought to alter the neural circuitry in the prefrontal cortex, amygdala, and structures that related to emotionality. Altered adult hippocampal neurogenesis may explain the cognitive deficits observed in depression [58]. GABAergic transmission plays an important role in the control of hippocampal neurogenesis and neural maturation, which are now established as cellular substrates of most, if not all, antidepressant therapies. Modest deficits in GABAergic transmission in GABA$_A$ receptor-deficient mice were found to be sufficient to cause behavioral, cognitive, neuroanatomical, and neuroendocrine phenotypes in an animal model of major depressive disorder (MDD) [61]. However, this does not mean that the GABA$_A$ receptor is not important in depression. Experiments carried out in GABA$_A_{31}$ and GABA$_A_{32}$ receptor knockout mice showed increased anxiety with an antidepressive phenotype [61]. Deficits in GABAergic transmission in the brain, discovered by proton magnetic resonance spectroscopy, are more severe in patients with unipolar than bipolar depression [61]. Decreased GABA levels have been found in the occipital cortex, anterior cingulate, and dorsomedial/dorsolateral prefrontal cortex of patients with MDD [61]. It has also been shown that GABA$_A$ receptor inhibitors produce antidepressant behavioral effects [62].

**Anxiety**

Given the role of GABAergic neurons in the acquisition, storage and extinction of fear memory [63], GABA$_A$ receptor modulators are used to treat anxiety. The fact that GABAergic deficits are observed in depressive disorders creates a compelling argument for the hypothesis that GABAergic neurons play a role in anxiety. Some specific subtypes of GABA$_A$ receptors are linked to signal transduction in interneurons [64]; therefore, these subtypes could play a role in mood, anxiety, and pain modulation. Thus, a reduction in GABA$_A$ receptors may underlie the deficits in GABAergic function observed in anxiety disorders and could modulate different forms of anxiety [61, 65]. In patients with generalized anxiety disorder, the number of GABA$_A$ receptors is reduced in the temporal lobe [26]. Patients with post-traumatic stress disorder (PTSD) also have lower levels of GABA in the medial prefrontal cortex [66]. Moreover, patients with panic disorder have reduced GABA$_A$ receptor numbers in the frontal, temporal, and parietal cortices; the left hippocampus; and the precuneus [67]. These observations show that, in various types of anxiety, the GABA$_A$ receptor is reduced in different brain regions [67]. Since the GABA$_A$ receptor can contribute to inhibition by moderating the activity of the GABA$_A$ receptor at presynaptic and postsynaptic sites, the GABA$_A$ receptor may also play a role in anxiety. Many types of anxiety have been linked to the GABA$_A$ receptor, including PTSD, social and specific phobias, and generalized anxiety disorder [44].

**LATER STAGE OF LIFE**

Today, there is an ever-increasing number of patients with...
neurodegenerative diseases, and diseases related to the brain are increasing steadily. The World Health Organization has predicted that two brain-related diseases—unipolar depression and cerebrovascular disease, which were ranked third and sixth, respectively, in 2004—will rank among the top five diseases in the world in the year 2030 [2, 68].

**Parkinson’s disease**

PD occurs at an annual rate of ~4.5–19 per 100,000 individuals [69]. This wide range is attributable to differences in age, sex, or other factors among sample groups. PD is well diagnosed globally, and the main symptoms include tremor and motor problems. Even though traditional methods of clinical diagnosis are sufficient for diagnosing PD, there are many ways of confirming the disease [2]. One method includes the detection of specific post-mortem changes in the expression of GABA_α_ receptor subunit genes in the substantia nigra (SN) and caudate nucleus (CN) of patients with PD [70]. GABA_α_ receptors, prominently including receptors containing the α4 subunit, are increased about 22-fold in these regions in PD [70]. Increases in the GABA_α_ receptor also induce increased tonic inhibition by astrocytes [15]. Non-motor problems, like depression, also occur in PD, and have been found to involve the lateral habenula (LHb) [71]. Upregulation of GABA_α_ receptors containing the α subunit and reduced release of GABA in the LHb appear to contribute to PD-related depression [71]. The density of GABA receptors varies between regions, with evidence for decreased GABA_β_ receptors in the putamen and external globus pallidus (GP). Since characteristic functions of the receptor in various regions reflect differences in receptor subtypes, knowledge about the subtypes involved is important for the development of drug treatments [72].

Reactive astrocytes release inhibitory GABA into the brain, a process that has been described in brain or spinal cord trauma, epilepsy, stroke, and neurodegenerative diseases [70, 72]. Reactive astrocytes have also been identified in PD, although the numbers of reactive astrocytes are low in PD [73].

**Alzheimer’s disease**

AD is the best-known disease to affect the elderly, afflicting up to 50% of people over the age of 85. The hallmark of AD, which is a representative age-related neurodegenerative disease, is memory loss. In addition to the impact on the AD patient, families of AD sufferers experience an enormous burden [74].

It has been shown that GABA levels are decreased in patients with AD; however, in AD, GABA is synthesized by activated astrocytes and GAT3/4 is secreted. Increased GABA levels have also been described in patients with AD [73]. This latter study reported that increased activation of GAD67 induced the synthesis of GABA in astrocytes, and this GABA was secreted into synapses by reverse-functioning astrocytic GAT3/4 [75]. The release of GABA causes tonic inhibition of perforant path/dentate granule cell synapses [76]. Under pathological conditions, reactive astrocytes release more GABA through the bestrophin 1 (Best1) channel. This GABA may activate GABA_α_ receptors in the extrasynaptic region and therefore confer inhibitory effects. Moreover, increased astrocytic GABA has been found in mouse brains, and this abnormal synthesis was found to be induced by monoamine oxidase B (MAOB) [77]. Cortical neurons adjacent to amyloid plaques exhibit a decrease in the number of GABAergic terminals. It has also been shown that the numbers of GABA_α_ and GABA_β_ receptors are increased in AD, and thus may become overactivated by the increased GABA levels observed in AD [78].

In summary, astrocytes exhibit increased expression of GAT, and synthesize and/or store and release GABA, which may increase tonic inhibition in their surrounding areas. In a mouse model of AD, increased tonic inhibition in the dentate gyrus was found following increases in astrocytic GABA. Taken together, these observations suggest that astrocytic GABA is an important player in the pathogenesis of AD [79].

**CONCLUSIONS**

The brain and brain diseases, long a subject of intense research interest, are increasingly a focus of the general population [80–85], possibly reflecting the high economic and societal burdens associated with brain diseases [86]. Brain disease can be classified according to age. About 15% of children in the USA experience neurodevelopmental disorders [87]; about 45% of adults experience mood disorders [87]; and about 50% of older adults have dementia, AD, or other neurodegenerative disorders [88]. In this review, we have taken a brief look at diseases that are linked to alterations in GABA receptors, such as receptor subunit mutations, reduced receptor function, reduced receptor number, and alterations in receptor density. These alterations, in turn, may lead to a reduction or increase in the effects of GABA at postsynaptic neurons.

GABA signaling may be a target for the treatment of diseases discussed in this review. Despite considerable research on the neuronal mechanisms and functions that underlie brain disease, studies on astrocytes and neuron-glial interactions in brain diseases are still limited. Moreover, although various analyses have been carried out on the role of GABA in various diseases, these experiments have necessarily been conducted at a relatively superficial level since a fundamental understanding of the mechanisms involved in each disease is lacking. To date, such studies have been
limited to an investigation of the phenotypes associated with the overexpression or inhibition/KO of GABA and/or GABA receptors [89, 90]. To gain a better understanding of the function of GABA in brain disorders, we must first have an understanding of its basic mechanisms. We hope that the introduction to GABA as a major inhibitory neurotransmitter and critical player in brain diseases provided by this review offers a more integrated view of the underlying scientific and social problems, and helps set the stage for more targeted investigations of detailed mechanisms.

ACKNOWLEDGEMENTS

This study was supported by grants from the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2016M3C7A1905074) and SGER program (NRF-2016R1D1A1A0293798) (B.E.Y).

REFERENCES

1. Grillner S, Ip N, Koch C, Koroschetz W, Okano H, Polachek M, Poo MM, Sejnowski TJ (2016) Worldwide initiatives to advance brain research. Nat Neurosci 19:1118-1122.
2. World Health Organization (2006) Neurological disorders: public health challenges. World Health Organization, Geneva.
3. Curtin SC, Warner M, Hedegaard H (2016) Increase in suicide in the United States, 1999-2014. NCHS Data Brief 1-8.
4. Masten AS, Faden VB, Zucker RA, Spear LP (2009) A developmental perspective on underage alcohol use. Alcohol Res Health 32:3-15.
5. Olesen J, Leonardi M (2003) The burden of brain diseases in Europe. Eur J Neurol 10:471-477.
6. Getahun D, Jacobsen SJ, Fassett MJ, Chen W, Demissie K, Rhoads GG (2013) Recent trends in childhood attention-deficit/hyperactivity disorder. JAMA Pediatr 167:282-288.
7. Substance Abuse and Mental Health Services Administration (US) (2009) Results from the 2008 national survey on drug use and health: national findings (office of applied studies, NSDUH series H-36. HHS publication No. SMA 09-4434). Substance Abuse and Mental Health Services Administration, Rockville, MD.
8. Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, Lee LC, Pettygrove S, Robinson C, Schulz E, Wells C, Wingate MS, Zahorodny W, Yargarin-Allsopp M; Centers for Disease Control and Prevention (CDC) (2016) Prevalence and characteristics of autism spectrum disorder among children aged 8 years--autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ 65:1-23.
9. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention (2012) Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 61:1-19.
10. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O'Shea DJ, Sohal VS, Goshen I, Finkelstein J, Paz JT, Stehfest K, Fudim R, Ramakrishnan C, Huguenard JR, Hegemann P, Deisseroth K (2011) Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477:171-178.
11. Schousboe A, Bak IK, Waagepetersen HS (2013) Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA. Front Endocrinol (Lausanne) 4:102.
12. Zhou Y, Danbolt NC (2014) Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna) 121:799-817.
13. Tritsch NX, Granger AJ, Sabatini BL (2016) Mechanisms and functions of GABA co-release. Nat Rev Neurosci 17:139-145.
14. Davis KL, Charney DC, Coyle JT, Nemeroﬀ C (2002) Neuro-psychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia, PA.
15. Farrant M, Nusser Z (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 6:215-229.
16. Carver CM, Reddy DS (2013) Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology (Berl) 230:151-188.
17. Stell BM, Mody I (2002) Receptors with different affinities mediate phasic and tonic GABA(A) conductances in hippocampal neurons. J Neurosci 22:RC223.
18. Braat S, Kooy RF (2015) The GABA(A) receptor as a therapeutic target for neurodevelopmental disorders. Neuron 86:1119-1130.
19. Pandolfo M (2011) Genetics of epilepsy. Semin Neurol 31: 506-518.
20. Yuan H, Low CM, Moody OA, Jenkins A, Traynelis SF (2015) Ionotropic GABA and glutamate receptor mutations and human neurologic diseases. Mol Pharmacol 88:203-217.
21. Rugg, Gunn FJ (2011) Adult onset epilepsies. In: Epilepsy 2015 from channels to commissioning: a practical guide to epilepsy (Rugg-Gunn FJ, Smalls JE, eds), pp 149-156. Interna-
22. Cryan JE, Kaumann K (2005) Don’t worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 26:36-43.

23. Tao W, Higgs MH, Spain WJ, Ransom CB (2013) Postsynaptic GABAB receptors enhance extrasynaptic GABA receptor function in dentate gyrus granule cells. J Neurosci 33:3738-3743.

24. Pizzarelli R, Cherubini E (2011) Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011:297153.

25. Giachino C, Barz M, Tchorz JS, Tome M, Gassmann M, Bischofberger J, Bettler B, Taylor V (2014) GABA suppresses neurogenesis in the adult hippocampus through GABAB receptors. Development 141:83-90.

26. Gross C, Hen R (2004) The developmental origins of anxiety. Nat Rev Neurosci 5:545-552.

27. Biederman J, Mick E, Faraone SV (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157:816-818.

28. Duncan NW, Wiebking C, Northoff G (2014) Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans—a review of multimodal imaging studies. Neurosci Biobehav Rev 47:36-52.

29. Kersanté F, Rowley SC, Pavlov I, Gutièrrez-Mecinas M, Semyanov A, Reul JM, W alker MC, Linthorst AC (2013) A functional role for both -aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus. J Physiol 591:2429-2441.

30. Yu Z, Fang Q, Xiao X, Wang YZ, Cai YQ, Cao H, Hu G, Chen Z, Fei J, Gong N, Xu TL (2013) GABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes. PLoS One 8:e69883.

31. Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, Nugent TF 3rd, Herman DH, Clasen LS, Toga AW, Rapoport JL, Thompson PM (2004) Dynamic mapping of human cortical development through childhood into early adulthood. Proc Natl Acad Sci USA 101:8174-8179.

32. Perou R, Bitsko RH, Blumberg SJ, Pastor P, Ghandour RM, Gfroerer JC, Hedden SL, Crosby AE, Visser SN, Schieve LA, Parks SE, Hall JE, Brody D, Simile CM, Thompson WW, Baio J, Avenevoli S, Kogan MD, Huang LN; Centers for Disease Control and Prevention (CDC) (2013) Mental health surveillance among children—United States, 2005-2011. MMWR Suppl 62:1-35.

33. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. American Psychiatric Association, Washington, D.C.

34. Pastor P, Reuben C, Duran C, Hawkins L (2015) Association between diagnosed ADHD and selected characteristics among children aged 4-17 years: United States, 2011-2013. NCHS Data Brief 201.

35. Sterley TL, Howells FM, Russell VA (2013) Evidence for reduced tonic levels of GABA in the hippocampus of an animal model of ADHD, the spontaneously hypertensive rat. Brain Res 1541:52-60.

36. Garbutt JC, van Kammen DP (1983) The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 9:336-353.

37. Comings DE (2001) Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann N Y Acad Sci 931:50-83.

38. Naaijen J, Bralten J, Poelmans G; IMAGE consortium, Glennon JC, Franke B, Buitelaar JK (2017) Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism. Transl Psychiatry 7:e999.

39. Sharp SI, McQuillin A, Gurling HM (2009) Genetics of attention-deficit hyperactivity disorder (ADHD). Neuropharmacology 57:590-600.

40. Sterley TL, Howells FM, Russell VA (2013) Maternal separation increases GABA(A) receptor-mediated modulation of norepinephrine release in the hippocampus of a rat model of ADHD, the spontaneously hypertensive rat. Brain Res 1497:23-31.

41. Tsai LY, Ghaziuddin M (2014) DSM-5 ASD moves forward into the past. J Autism Dev Disord 44:321-330.

42. Lee E, Lee J, Kim E (2017) Excitation/inhibition imbalance in animal models of autism spectrum disorders. Biol Psychiatry 81:838-847.

43. Supekar K, Uddin LQ, Khouzam A, Phillips J, Gaillard WD, Kenworthy LE, Yerys BE, Vaidya CJ, Menon V (2013) Brain hyperconnectivity in children with autism and its links to social deficits. Cell Reports 5:738-747.

44. El-Ansary A, Al-Ayadhi L (2014) GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders. J Neuroinflammation 11:189.

45. Heaney CF, Kinney JW (2016) Role of GABA(B) receptors in learning and memory and neurological disorders. Neurosci Biobehav Rev 63:1-28.

46. Shakirullah, Ali N, Khan A, Nabi M (2014) The prevalence, incidence and etiology of epilepsy. Int J Clin Exp Neurol 2:29-
39. Featherstone V (2010) Epilepsy in children and young people. Cerebra, Carmarthe.
48. Carney P, Prowse MA, Scheffer IE (2005) Epilepsy syndromes in children. Aust Fam Physician 34:1009-1015.
49. Salpekar JA, Mishra G (2014) Key issues in addressing the comorbidity of attention deficit hyperactivity disorder and pediatric epilepsy. Epilepsy Behav 37:310-315.
51. Jokiranta E, Sourander A, Suominen A, Timonen-Soivio L, Brown AS, Sillanpää M (2014) Epilepsy among children and adolescents with autism spectrum disorders: a population-based study. J Autism Dev Disord 44:2547-2557.
52. Shetty AK, Upadhya D (2016) GABA-ergic cell therapy for epilepsy: advances, limitations and challenges. Neurosci Biobehav Rev 62:35-47.
55. Unichenko P, Kirischuk S, Luhmann HJ (2015) GABA transporters control GABAergic neurotransmission in the mouse subplate. Neuroscience 304:217-227.
56. Lam PM, Carlsen J, González MI (2017) A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. Neurobiol Dis 102:1-10.
57. Pratt LA, Brody DJ (2014) Depression in the U.S. household population, 2009-2012. NCHS Data Brief 1-8.
58. Sahay A, Hen R (2007) Adult hippocampal neurogenesis in depression. Nat Neurosci 10:1110-1115.
59. Gilman SE, Kawachi I, Fitzmaurice GM, Buka SL (2003) Family disruption in childhood and risk of adult depression. Am J Psychiatry 160:939-946.
60. Kessler RC (2012) The costs of depression. Psychiatr Clin North Am 35:1-14.
61. Luscher B, Shen Q, Sahir N (2011) The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 16:383-406.
62. Couve A, Moss SJ, Pangalos MN (2000) GABAB receptors: a new paradigm in G protein signaling. Mol Cell Neurosci 16:296-312.
63. Kaluuff AV, Nutt DJ (2007) Role of GABA in anxiety and depression. Depress Anxiety 24:495-517.
64. Möhler H (2012) The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 62:42-53.
65. Kaluuff AV, Nutt DJ (1996-1997) Role of GABA in memory and anxiety. Depress Anxiety 4:100-110.
66. Trousselleard M, Lefebvre B, Caillet L, Andruetan Y, de Montleau F, Denis J, Canini F (2016) Is plasma GABA level a biomarker of post-traumatic stress disorder (PTSD) severity? A preliminary study. Psychiatry Res 241:273-279.
67. Fatemi SH, Folsom TD (2015) GABA receptor subunit distribution and FMRI mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism. Schizophr Res 167:42-56.
68. World Health Organization (2008) The global burden of disease: 2004 update. World Health Organization, Geneva.
69. de Lau LM, Breiter MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525-535.
70. Luchetti S, Huitinga I, Swaab DF (2011) Neurosteroid and GABA-A receptor alterations in Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Neuroscience 1916-21.
71. Wang T, Zhang L, Zhang QJ, Wang Y, Du CX, Sun YN, Zhang J, Lv SX, Chen L, Liu J (2017) Involvement of lateral habenula a1 subunit-containing GABAA receptor-mediated inhibitory transmission in the regulation of depression-related behaviors in experimental Parkinson’s disease. Neuropharmacology 116:399-411.
72. Brichta L, Greengard P, Flajolet M (2013) Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. Trends Neurosci 36:543-554.
73. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23:474-483.
74. Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 12:459-509.
75. Wu Z, Guo Z, Gearing M, Chen G (2014) Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s [corrected] disease model. Nat Commun 5:4159.
76. De Strooper B, Karran E (2016) The cellular phase of Alzheimer’s disease. Cell 164:603-615.
77. Jo S, Varishkin O, Hwang YI, Chun YE, Park M, Woo DH, Bae JY, Kim T, Lee J, Chun H, Park HJ, Lee DY, Hong J, Kim HY, Oh SJ, Park SJ, Lee H, Yoon BE, Kim Y, Jeong Y, Shin I, Bae YC, Cho J, Kowall NW, Ryu H, Hwang E, Kim D, Lee CJ (2014) GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med 20:886-896.
78. Li Y, Sun H, Chen Z, Xu H, Bu G, Zheng H (2016) Implications of GABAergic neurotransmission in Alzheimer’s disease. Front Aging Neurosci 8:31.
79. Osborn LM, Kamphuis W, Wadman WJ, Hol EM (2016) Astroglisis: an integral player in the pathogenesis of Alzheimer's disease. Prog Neurobiol 144:121-141.

80. Australian Brain Alliance Steering Committee. Electronic address: richards@uq.edu.au; Australian Brain Alliance Steering Committee (2016) Australian brain alliance. Neuron 92:597-600.

81. Jabalpurwala I (2016) Brain Canada: one brain one community. Neuron 92:601-606.

82. Okano H, Sasaki E, Yamamori T, Iriki A, Shimogori T, Yamaguchi Y, Kasai K, Miyawaki A (2016) Brain/MINDS: a Japanese national brain project for marmoset neuroscience. Neuron 92:582-590.

83. Poo MM, Du JL, Ip NY, Xiong ZQ, Xu B, Tan T (2016) China brain project: basic neuroscience, brain diseases, and brain-inspired computing. Neuron 92:591-596.

84. Amunts K, Ebull C, Muller J, Telefont M, Knoll A, Lippert T (2016) The human brain project: creating a European research infrastructure to decode the human brain. Neuron 92:574-581.

85. Jeong SJ, Lee H, Hur EM, Choe Y, Koo JW, Rah JC, Lee KJ, Lim HH, Sun W, Moon C, Kim K (2016) Korea brain initiative: integration and control of brain functions. Neuron 92:607-611.

86. DiLuca M, Olesen J (2014) The cost of brain diseases: a burden or a challenge? Neuron 82:1205-1208.

87. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:593-602.

88. Niccoli T, Partridge L (2012) Ageing as a risk factor for disease. Curr Biol 22:R741-R752.

89. Hanchar HJ, Dodson PD, Olsen RW, Otis TS, Wallner M (2005) Alcohol-induced motor impairment caused by increased extrasynaptic GABA(A) receptor activity. Nat Neurosci 8:339-345.

90. Cope DW, Di Giovanni G, Fyson SI, Orban G, Errington AC, Lorincz ML, Gould TM, Carter DA, Crunelli V (2009) Enhanced tonic GABAA inhibition in typical absence epilepsy. Nat Med 15:1392-1398.